Skip to main content

Table 4 Multivariate stepwise regression analyses of data from 147 patients with axial spondyloarthritis followed over 2 years assessing the associations between treatment and development of erosion or fat metaplasia

From: Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis

  β coefficient SE t value P value
TNFα inhibitor treatment −1.33 0.47 −3.0 0.003
2 year change in SPARCC SIJ inflammation score 0.09 0.036 2.57 0.012
Baseline SSS erosion score −0.40 0.059 −7.1 <0.0001
  1. Dependent variable: 2-year change in SSS for erosion. Adjusted R2 = 0.45. Variables not included in the model: age, sex, symptom duration, baseline Ankylosing Spondylitis Disease Activity Score, baseline SPARCC SIJ inflammation score, and baseline SSS for ankylosis. SE, standard error; SIJ, sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS, Sacroiliac Joint Structural Score; TNFα, tumor necrosis factor alpha.